Rational Second-Generation Antiandrogen Use in Prostate Cancer.

ABSTRACT: The second-generation antiandrogens have achieved an ever-growing list of approvals and indications in subsets of prostate cancer. Here, we provide an overview of second-generation antiandrogen trials and FDA approvals and outline a rational sequencing approach for the use of these agents as they relate to chemotherapy and other available treatment modalities in advanced prostate cancer. All published phase II-III randomized controlled trials reporting outcomes with the use of second-generation antiandrogens in prostate cancer are included as well as all published trials and retrospective studies of second-generation antiandrogen sequencing and/or combinations. Complete tabular and graphical representation of all available evidence is provided regarding the use and sequencing of second-gen

SUBMITTER: Orme JJ 

PROVIDER: S-EPMC8895732 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature